Key facts
- It has raised $200K; the latest was Accelerator/Incubator ($100K) in Oct 2025.
- Notable investors include Right Side Capital Management, gener8tor.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Cryton Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Cryton Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cryton Biosciences
Operator of a biotechnology company intended to redefine cancer treatment by targeting mitochondrial metabolism to halt cancer progression and restore immune function. The company offers a pioneering dual-action therapeutic approach that selectively exploits metabolic vulnerabilities in cancer cells while restoring immune cell balance, enabling customers to access novel therapies that overcome resistance, improve survival outcomes and bring renewed hope where traditional treatments have failed.
- Sector
- Healthcare
- HQ
- Austin, MN, United States
- Website
- crytonbio.com/
- Ownership
- Privately Held (backing)
Cryton Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cryton Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cryton Biosciences in its N-PORT filings yet. We sweep new filings monthly.